Computed Tomography Morphological Classification of Lung Adenocarcinoma and Its Correlation with Epidermal Growth Factor Receptor Mutation Status: A Report of 1075 Cases

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Pascoe HM, Knipe HC, Pascoe D, Heinze SB. The many faces of lung adenocarcinoma: a pictorial essay. J Med Imaging Radiat Oncol. 2018;62:654–661. doi:10.1111/1754-9485.12779
   PubMed Web of Science ®Google Scholar
• Saito M, Shiraishi K, Kunitoh H, et al. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107(6):713–720. doi:10.1111/cas.12941
   PubMed Web of Science ®Google Scholar
• Jin Y, Shi X, Zhao J, et al. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer. 2018;124:110–116. doi:10.1016/j.lungcan.2018.07.039
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012;13:239–246. doi:10.1016/S1470-2045(11)70393-X
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–308. doi:10.1016/S1470-2045(11)70385-0
   PubMed Web of Science ®Google Scholar
• Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280(1):271–280. doi:10.1148/radiol.2016151455
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. International Association for theStudy of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285.
   PubMed Web of Science ®Google Scholar
• Cohen JG, Reymond E, Jankowski A, et al. Lung adenocarcinomas: correlation of computed tomography and pathology findings. Diagn Interv Imaging. 2016;97(10):955–963. doi:10.1016/j.diii.2016.06.021
   PubMed Web of Science ®Google Scholar
• Hutchinson BD, Shroff GS, Truong MT, et al. Spectrum of lung adenocarcinoma. Semin Ultrasound CT MR. 2019;40(3):255–264. doi:10.1053/j.sult.2018.11.009
   PubMed Web of Science ®Google Scholar
• Moon Y, Lee KY, Park JK. The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection. J Thorac Dis. 2017;9(10):3782–3792. doi:10.21037/jtd.2017.09.40
   PubMed Web of Science ®Google Scholar
• Lederlin M, Puderbach M, Muley T, et al. Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. Eur Respir J. 2013;41(4):943–951. doi:10.1183/09031936.00056612
   PubMed Web of Science ®Google Scholar
• Xue X, Wang P, Xue Q, et al. Comparative study of solitary thin-walled cavity lung cancer with computed tomography and pathological findings. Lung Cancer. 2012;78(1):45–50. doi:10.1016/j.lungcan.2012.06.004
   PubMed Web of Science ®Google Scholar
• Tan Y, Gao J, Wu C, et al. CT characteristics and pathologic basis of solitary cystic lung cancer. Radiology. 2019;291(2):495–501. doi:10.1148/radiol.2019181598
   PubMed Web of Science ®Google Scholar
• Mansuet-Lupo A, Barritault M, Alifano M, et al. Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J Thorac Oncol. 2019;14(5):844–856. doi:10.1016/j.jtho.2019.01.017
   PubMed Web of Science ®Google Scholar
• Chung JH, Choe G, Jheon S, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol. 2009;4(12):1490–1495. doi:10.1097/JTO.0b013e3181bc9731
   PubMed Web of Science ®Google Scholar
• Revel MP, Carette MF, Torrent M, et al. Diagnosis and standardized report for non-small cell lung cancer. Diagn Interv Imaging. 2014;95(7–8):727–738. doi:10.1016/j.diii.2014.06.007
   PubMed Web of Science ®Google Scholar
• Herrera LS, Fernandez-Fabrellas E, Juan SG, et al. Predicting malignant and paramalignant pleural effusions by combining clinical, radiological and pleural fluid analytical parameters. Lung. 2017;195(5):653–660. doi:10.1007/s00408-017-0032-3
   PubMed Web of Science ®Google Scholar
• Yang MF, Tong ZH, Wang Z, et al. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion. Eur J Nucl Med Mol Imaging. 2019;46(7):1457–1467. doi:10.1007/s00259-019-04287-7
   PubMed Web of Science ®Google Scholar
• Brun C, Gay P, Cottier M, et al. Comparison of cytology, chest computed and positron emission tomography findings in malignant pleural effusion from lung cancer. J Thorac Dis. 2018;10(12):6903–6911. doi:10.21037/jtd.2018.11.127
   PubMed Web of Science ®Google Scholar
• Sabri A, Batool M, Xu Z, et al. Predicting EGFR mutation status in lung cancer: proposal for a scoring model using imaging and demographic characteristics. Eur Radiol. 2016;26(11):4141–4147. doi:10.1007/s00330-016-4252-3
   PubMed Web of Science ®Google Scholar
• Zhang H, Cai W, Wang Y, et al. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2019;24(6):649–659. doi:10.1007/s10147-019-01403-3
   PubMed Web of Science ®Google Scholar
• Hong SJ, Kim TJ, Choi YW, et al. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: imaging features and histological subtypes. Eur Radiol. 2016;26(10):3660–3668. doi:10.1007/s00330-015-4196-z
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang Y, Ma L, et al. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma. Eur J Radiol. 2019;112:44–51. doi:10.1016/j.ejrad.2019.01.005
   PubMed Web of Science ®Google Scholar
• Wu S, Shen G, Mao J, et al. CT radiomics in predicting EGFR mutation in non-small cell lung cancer: a Single Institutional Study. Front Oncol. 2020;10:542957. doi:10.3389/fonc.2020.542957
   PubMed Web of Science ®Google Scholar
• Tu W, Sun G, Fan L, et al. Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer. 2019;132:28–35. doi:10.1016/j.lungcan.2019.03.025
   PubMed Web of Science ®Google Scholar
• Jia TY, Xiong JF, Li XY, et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. Eur Radiol. 2019;29(9):4742–4750. doi:10.1007/s00330-019-06024-y
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang W, Wang K, et al. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma. Medicine (Baltimore). 2018;97(26):e11116. doi:10.1097/MD.0000000000011116
   PubMed Web of Science ®Google Scholar
• Motono N, Funasaki A, Sekimura A, et al. Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma. Med Oncol. 2018;35(3):22. doi:10.1007/s12032-018-1082-y
   PubMed Web of Science ®Google Scholar
• Onoda H, Kimura T, Tao H, et al. Air bronchogram in pleomorphic carcinoma of the lung is associated with favorable prognosis. Thorac Cancer. 2018;9(6):718–725. doi:10.1111/1759-7714.12638
   PubMed Web of Science ®Google Scholar
• Guo H, Shen-Tu Y. [Research progress in diagnosis and management strategies of multiple primary lung cancer]. Zhongguo Fei Ai Za Zhi. 2016;19(5):307–311. (Chinese). doi:10.3779/j.issn.1009-3419.2016.05.12
   PubMedGoogle Scholar
• Yu JY, Yu SF, Wang SH, et al. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chin J Cancer. 2016;35:30. doi:10.1186/s40880-016-0086-2
   PubMedGoogle Scholar
• Won YW, Han JY, Lee GK, et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol. 2011;64(11):947–952. doi:10.1136/jclinpath-2011-200169
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967. doi:10.1056/NEJMoa0904554
   PubMed Web of Science ®Google Scholar